Officials at NHS England have been accused of interfering in a process to decide whether a drug which can cure Hepatitis C should be made available to patients on the health service.
Harvoni, which is a combination of two new generation hepatitis C drugs, is currently being appraised by the National Institute for Health and Care Excellence.
But at a meeting at NICE on April 1, it is claimed that two senior NHS England officials reminded those attending that they had to take into account the cost to the health service when deciding whether to approve any treatment.
This is, in fact, not true. NICE does not focus on affordability but rather on cost-effectiveness.
- See more at: http://blogs.channel4.com/victoria-macdonald-on-health-and-social-care/nhs-england-accused-interfering-approval-hep-drug/3011#sthash.rkyi6yYa.dpuf
No comments:
Post a Comment